Conferences - Results from #8300

Viewing 8301-8320 of 11775 articles

ASCO GU 2018: Impact of Genomic Risk Scores on Treatment Decisions Following Radical Prostatectomy in a Prospective Medicare Registry

ASCO GU 2018: Adjuvant Enzalutamide (ENZA) for Men with Non-metastatic High-risk Prostate Cancer (HRPCa) After Radical Prostatectomy (RP).

ASCO GU 2018: Lu-177-labeled PSMA-I&T Radioligand Therapy for mCRPC

ASCO GU 2018: Daily Versus Weekly Prostate Cancer image-guided Radiotherapy: A Phase 3, Multi-center, Randomized Trial

ASCO GU 2018: Comparison of Enzalutamide and Bicalutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer - STRIVE Study

ASCO GU 2018: Treatment Duration And Utilization Patterns In Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide or Abiraterone Acetate

ASCO GU 2018: Debate: Is there Evidence for Local treatment in Patients with Newly Diagnosed Metastatic Disease?

ASCO GU 2018: Impact Of Statins On Outcomes In Patients With mCRPC: COU-AA-301 and COU-AA-302 Trials

ASCO GU 2018: Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes

ASCO GU 2018: Pembrolizumab for Recurrent or Advanced Prostate Cancer

ASCO GU 2018: Effects Of a 6-month Moderate-intensity Exercise Program on Metabolic Parameters and Bone Mineral Density in Men on Androgen Deprivation Therapy for Prostate Cancer

ASCO GU 2018: Outcomes in Patients with Advanced Prostate Cancer And Inactivating Germline Mutations in BRCA2 or ATM

ASCO GU 2018: Incorporating Genomics Into the Management of Systemic Therapy: Advances and Practicality

ASCO GU 2018: Impact of Sexual Orientation on Contemporary Rates of Prostate Cancer Screening

ASCO GU 2018: Why are Low-risk Prostate Cancers (Pca) Treated Aggressively? A Population-based Cohort Analysis

ASCO GU 2018: Statin use and Outcomes of Patients with mCRPC Being Treated with Abiraterone

ASCO GU 2018: A National Survey of Radiation Oncologists and Urologists on Active Surveillance for Low-risk Prostate Cancer

ASCO GU 2018: When Can Active Surveillance Be Less Active? Prediction of Long-term Non-reclassification for Men with Low-risk Prostate Cancer

ASCO GU 2018: TPS 159 -What Fixes PSA Screening Guidelines Gone Wrong?

ASCO GU 2018: Can free PSA be used as a biomarker in biochemical recurrence after surgery to predict CRPC?

411
412
413
414
415
416
417
418
419
420